Ibuprofen Kabi (Ibuprofen)

Ibuprofen works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it reduces pain signaling, lowers fever, and diminishes inflammatory swelling.

The specific dose and infusion rate of Ibuprofen Kabi are determined by the prescribing clinician based on the patient’s condition, weight, renal function and other clinical factors. Healthcare professionals should follow local guidelines and product labeling when prescribing.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Ibuprofen Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with other IV NSAIDs, ibuprofen offers a well‑characterised safety profile and effective analgesia at lower gastrointestinal risk than some COX‑2 selective agents. Unlike opioids, it does not cause respiratory depression, but it shares class‑related risks such as renal impairment and bleeding, which must be weighed against therapeutic benefits.

Ibuprofen Kabi must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or agitate the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Ibuprofen Kabi is given by intravenous infusion. The medication is diluted according to the manufacturer’s instructions and administered over a short period, typically 15–30 minutes, under the supervision of qualified healthcare personnel in a clinical setting.

Serious risks include gastrointestinal bleeding or ulceration, acute kidney injury, severe allergic reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, renal dysfunction, or hypersensitivity during treatment.

Ibuprofen Kabi is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding, severe renal or hepatic impairment, and in those who have experienced a previous severe reaction to any COX‑inhibiting drug. Caution is also advised for patients with uncontrolled hypertension or cardiovascular disease.